Categories
CoronaVirus News

CureVac’s stock soars on GSK’s $1.56 billion deal for COVID-19 and flu vaccines – MarketWatch


  1. CureVac’s stock soars on GSK’s $1.56 billion deal for COVID-19 and flu vaccines  MarketWatch
  2. GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac  Forbes
  3. GSK buys COVID, influenza vaccines from retrenching CureVac  Reuters.com